Diabetes Care, Vol 21, Issue 11 1910-1914, Copyright © 1998 by American Diabetes Association

ARTICLES

Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart

L Heinemann, C Weyer, M Rauhaus, S Heinrichs and T Heise
Department of Metabolic Diseases and Nutrition, WHO Collaborating Centre for Diabetes, Heinrich-Heine University, Dusseldorf, Germany. lutz.heinemann@uni-duesseldorf.de

OBJECTIVE: To study the intra- and interindividual variability of the metabolic activity of soluble insulin and of the rapid-acting insulin analog insulin aspart after subcutaneous injection. RESEARCH DESIGN AND METHODS: A total of nine healthy male volunteers received subcutaneous injections of soluble insulin (0.2 U/kg) in the abdominal region on each of the four study days. Another 10 volunteers received an injection of insulin aspart four times. Glucose infusion rates necessary to neutralize the blood glucose-lowering effect of the administered insulin were registered during euglycemic glucose clamps (blood glucose 5.0 mmol/l; basal intravenous insulin infusion 0.15 mU x kg(-1) x min(-1) over the subsequent 600 min. We investigated the variation in metabolic activity by calculating coefficients of variation (CVs). RESULTS: In comparison to soluble insulin, subcutaneous injections of insulin aspart led to a more rapid onset of action and a shorter duration of action. Subcutaneous injection of the insulin preparations resulted in intraindividual CVs of the summary measures between 10 and 30% (soluble insulin vs. insulin aspart: maximal metabolic activity 15+/-7 vs. 16+/-10%, time to maximal metabolic activity 14+/-10 vs. 11+/-6%; NS between the preparations [means +/- SD]). The decline to half-maximal activity after maximal activity showed a lower intraindividual CV with insulin aspart (19+/-9 vs. 11+/-5%; P = 0.018). The interindividual CVs were higher than the intraindividual CVs (26 vs. 28, 23 vs. 19, and 26 vs. 17%). Generally, the pharmacodynamic variability was higher than the pharmacokinetic variability. For the pharmacokinetic measures, the intra- and interindividual variability in t(max) was lower for insulin aspart than for soluble insulin. CONCLUSIONS: The metabolic effect of soluble insulin shows an intraindividual variability of 10-20% in healthy volunteers, even under strictly controlled experimental conditions. The overall variability of action of insulin aspart was comparable to that of soluble insulin.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Hartman Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence Clin. Med. Res., September 1, 2008; 6(2): 54 - 67. [Abstract] [Full Text] [PDF]

				K. L. Swan, S. A. Weinzimer, J. D. Dziura, G. M. Steil, G. R. Voskanyan, A. T. Steffen, M. L. Martin, and W. V. Tamborlane Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes Diabetes Care, January 1, 2008; 31(1): 44 - 46. [Full Text] [PDF]

				J. R. Gavin III Practical Approaches to Insulin Therapy The Diabetes Educator, March 1, 2007; 33(Supplement_3): 66S - 73S. [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				K. Rave, S. Bott, L. Heinemann, S. Sha, R. H.A. Becker, S. A. Willavize, and T. Heise Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin Diabetes Care, May 1, 2005; 28(5): 1077 - 1082. [Abstract] [Full Text] [PDF]

				C. Weyer, M. S. Fineman, S. Strobel, L. Shen, J. Data, O. G. Kolterman, and M. F. Sylvestri Properties of pramlintide and insulin upon mixing Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 816 - 822. [Abstract] [Full Text] [PDF]

				T. Heise, L. Nosek, B. B. Ronn, L. Endahl, L. Heinemann, C. Kapitza, and E. Draeger Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes Diabetes, June 1, 2004; 53(6): 1614 - 1620. [Abstract] [Full Text] [PDF]

				A. D. Cherrington, D. W. Neal, D. S. Edgerton, D. Glass, L. Bowen, C. H. Hobbs, C. Leach, R. Rosskamp, and T. R. Strack Inhalation of Insulin in Dogs: Assessment of Insulin Levels and Comparison to Subcutaneous Injection Diabetes, April 1, 2004; 53(4): 877 - 881. [Abstract] [Full Text] [PDF]

				R. R. Henry, S. Mudaliar, N. Chu, D. Kim, D. Armstrong, T. T. Davis, B. An, and R. R. Reinhardt Young and Elderly Type 2 Diabetic Patients Inhaling Insulin with the AERx(R) Insulin Diabetes Management System: A Pharmacokinetic and Pharmacodynamic Comparison J. Clin. Pharmacol., November 1, 2003; 43(11): 1228 - 1234. [Abstract] [Full Text] [PDF]

				A. D. Perera, C. Kapitza, L. Nosek, R. S. Fishman, D. A. Shapiro, T. Heise, and L. Heinemann Absorption and Metabolic Effect of Inhaled Insulin: Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes Diabetes Care, December 1, 2002; 25(12): 2276 - 2281. [Abstract] [Full Text] [PDF]

				D. R. Owens Optimising glycaemic control -- the role of long-acting insulin analogues in basal insulin therapy The British Journal of Diabetes & Vascular Disease, September 1, 2002; 2(5): 403 - 406. [Abstract] [PDF]

				T. Lindstrom, C. A. Hedman, and H. J. Arnqvist Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs Diabetes Care, June 1, 2002; 25(6): 1049 - 1054. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				A. Plum, H. Agersø, and L. Andersen Pharmacokinetics of the Rapid-Acting Insulin Analog, Insulin Aspart, in Rats, Dogs, and Pigs, and Pharmacodynamics of Insulin Aspart in Pigs Drug Metab. Dispos., February 1, 2000; 28(2): 155 - 160. [Abstract] [Full Text]